Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Clinical trial NCT02766335 · COMPLETED
Trial details
- NCT number
- NCT02766335
- Sponsor
- SWOG Cancer Research Network
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-31
- Primary completion
- 2018-09-01
- Enrollment
- 116
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.